These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 39014082)

  • 1. Identification of a pro-protein synthesis osteosarcoma subtype for predicting prognosis and treatment.
    Yi C; Liu J; Zhao S; Gong D; Xu B; Li A; Bian E; Tian D
    Sci Rep; 2024 Jul; 14(1):16475. PubMed ID: 39014082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Develop a Novel Signature to Predict the Survival and Affect the Immune Microenvironment of Osteosarcoma Patients: Anoikis-Related Genes.
    Yang M; Su Y; Xu K; Zheng H; Cai Y; Wen P; Yang Z; Liu L; Xu P
    J Immunol Res; 2024; 2024():6595252. PubMed ID: 39431237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma.
    Li Q; Huang X; Zhao Y
    Cancer Biother Radiopharm; 2024 Sep; 39(7):502-516. PubMed ID: 37889617
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel risk score model based on eight genes and a nomogram for predicting overall survival of patients with osteosarcoma.
    Wu G; Zhang M
    BMC Cancer; 2020 May; 20(1):456. PubMed ID: 32448271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic signature related to programmed cell death in osteosarcoma.
    Jiang YC; Xu QT; Wang HB; Ren SY; Zhang Y
    Front Immunol; 2024; 15():1427661. PubMed ID: 39015570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.
    Pan F; Pan R; Hu R; Zhang H; Lei S; Zhang L; Zhou C; Zeng Z; Tian X; Xie Q
    J Cell Mol Med; 2024 May; 28(10):e18395. PubMed ID: 38774995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Signature in Osteosarcoma Based on Amino Acid Metabolism-Associated Genes.
    Feng L; Chen Y; Mei X; Wang L; Zhao W; Yao J
    Cancer Biother Radiopharm; 2024 Sep; 39(7):517-531. PubMed ID: 38512709
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis.
    Shi S; Zhang L; Guo X
    Front Immunol; 2024; 15():1424950. PubMed ID: 39108264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-1296-5p suppresses the proliferation, migration, and invasion of human osteosarcoma cells by targeting NOTCH2.
    Wang L; Hu K; Chao Y; Wang X
    J Cell Biochem; 2020 Feb; 121(2):2038-2046. PubMed ID: 31633240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of TNFRSF1A as a potential biomarker for osteosarcoma.
    Zhang Y; Liu K; Wang J
    Cancer Biomark; 2024; 39(4):299-312. PubMed ID: 38250759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
    Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
    BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma.
    Zheng S; Cheng X; Ke S; Zhang L; Wu H; He D; Cheng X
    Aging (Albany NY); 2024 May; 16(9):8155-8170. PubMed ID: 38747739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation.
    Zhang Z; Liu B; Lin Z; Mei L; Chen R; Li Z
    FASEB J; 2024 Jul; 38(14):e23783. PubMed ID: 39037571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning survival prediction using tumor lipid metabolism genes for osteosarcoma.
    Li S; Zheng Z; Wang B
    Sci Rep; 2024 Jun; 14(1):12934. PubMed ID: 38839983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and validation of a novel NAD
    Yu R; Lu G; Cheng B; Li J; Jiang Q; Lan X
    J Orthop Res; 2024 May; 42(5):1086-1103. PubMed ID: 38047487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma.
    Wang L; Liu Y; Tai J; Dou X; Yang H; Li Q; Liu J; Yan Z; Liu X
    Sci Rep; 2024 Apr; 14(1):9186. PubMed ID: 38649690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
    Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
    Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma.
    Xu A; Qian C; Lin J; Yu W; Jin J; Liu B; Tao H
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
    Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
    BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma.
    Wang H; Tao Y; Han J; Shen J; Mu H; Wang Z; Wang J; Jin X; Zhang Q; Yang Y; Lin J; Sun M; Ma X; Ren L; LeBlanc AK; Xu J; Hua Y; Sun W
    Cell Oncol (Dordr); 2024 Oct; 47(5):1845-1861. PubMed ID: 39115605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.